LCTX 주가 차트
LCTX 수입
Lineage Cell Therapeutics Inc
$1.34
5.07%
$0.06
오늘 기준:May 14, 14:25:59 GMT-4
뒤로
Lineage Cell Therapeutics Inc (LCTX) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-05-12
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
LCTX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Lineage Cell Therapeutics Inc LCTX의 지난 분기 매출 실적은 어땠나요?
Lineage Cell Therapeutics Inc의 매출 추정치는 얼마인가요?
Lineage Cell Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Lineage Cell Therapeutics Inc는 언제 수익을 보고하나요?
Lineage Cell Therapeutics Inc의 예상 수익은 얼마인가요?
Lineage Cell Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.28
시가
$1.27
일일 범위
$1.24 - $1.35
52주 범위
$0.45 - $2.09
거래량
1.1M
평균 거래량
1.1M
배당수익률
--
EPS(TTM)
-0.28
시가총액
$335.0M
LCTX란 무엇인가요?
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The firm programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
